Viral interference with antigen presentation

Nature Immunology

Volumn 3, Issue 11, 2002, Pages 1019-1025

  Yewdell, Jonathan W ^a   Hill, Ann B ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GENE PRODUCT; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; VIRUS PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA VIRUS; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS; HERPES VIRUS; HOST CELL; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR EVOLUTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RNA VIRUS; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INFECTION; VIRUS MUTANT; VIRUS TRANSMISSION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HAPLORHINI; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICE; MODELS, IMMUNOLOGICAL; SPECIES SPECIFICITY; VIRAL PROTEINS; VIRUSES;

EID: 0036852231     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni1102-1019     Document Type: Review

References (80)

1. Blanden, R. V. Mechanisms of recovery from a generalized viral infection: mousepox. I. The effects of anti-thymocyte serum. J. Exp. Med. 132, 1035-1054 (1970).
2. Blanden, R. V. Mechanisms of recovery from a generalized viral infection: mousepox. II. Passive transfer of recovery mechanisms with immune lymphoid cells. J. Exp. Med. 133, 1074-1089 (1971).
3. Blanden, R. V. Mechanisms of recovery from a generalized viral infection: mousepox. 3. Regression infectious foci. J. Exp. Med. 133, 1090-1104 (1971).
4. Walter, E. A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Eng. J. Med. 333, 1038-1044 (1995).
5. Brodie, S. J. et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med. 5, 34-41 (1999).
6. Khanna, R. et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with post-transplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 96, 10391-10396 (1999).
7. Gadola, S. D., Moins-Teisserenc, H. T., Trowsdale, J., Gross, W. L. & Cerundolo, V. TAP deficiency syndrome. Clin. Exp. Immunol. 121, 173-178 (2000).
8. Rock, K. L. & Goldberg, A. L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17, 739-779 (1999).
9. Pamer, E. & Cresswell, P. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16, 323-358 (1998).
10. Yewdell, J. W., Schubert, U. & Bennink, J. R. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J. Cell Sci. 114, 845-851 (2001).
11. Yewdell, J. W. & Bennink, J. R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88 (1999).
12. Posavad, C. M., Newton, J. J. & Rosenthal, K. L. Infection and inhibition of human cytotoxic T lymphocytes by herpes simplex virus. J. Virol. 68, 4072-4074 (1994).
13. Andrews, D. M., Andoniou, C. E., Granucci, F., Ricciardi-Castagnoli, P. & Degli-Esposti, M. A. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nature Immunol. 2, 1077-1084 (2001).
14. Moutaftsi, M., Mehl, A. M., Borysiewicz, L. K. & Tabi, Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 99, 2913-2921 (2002).
15. Engelmayer, J. et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163, 6762-6768 (1999).
16. Salio, M., Cella, M., Suter, M. & Lanzavecchia, A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol. 29, 3245-3253 (1999).
17. + T cells by infected dendritic cells in vivo. Nature Immunol. 3, 265-271 (2002).
18. Bridgeman, A., Stevenson, P. G., Simas, J. P. & Efstathiou, S. A secreted chemokine binding protein encoded by murine γ herpesvirus-68 is necessary for the establishment of a normal latent load. J. Exp. Med. 194, 301-312 (2001).
19. Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J. & Ploegh, H. L. Viral subversion of the immune system. Annu. Rev. Immunol. 18, 861-926 (2000).
20. Alcami, A. & Koszinowski, U. H. Viral mechanisms of immune evasion. Immunol. Today 21, 447-55 (2000).
21. Yewdell, J. W. & Bennink, J. R. Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu. Rev. Cell Dev. Bio. 15, 579-606 (1999).
22. Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143, 1283-1288 (1976).
23. Levitskaya, J. et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688 (1995).
24. + T cell responses to EBV EBNAI: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7, 791-802 (1997).
25. Sigal, L. J. & Rock, K. L. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and - independent pathways of antigen presentation. J. Exp. Med. 192, 1143-1150 (2000).
26. Prasad, S. A., Norbury, C. C., Chen, W., Bennink, J. R. & Yewdell, J. W. Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J. Immunol. 166, 4809-4812 (2001).
27. + T cells in vivo. J. Immunol. 166, 4355-4362 (2001).
28. + T cells. J. Immunol. 168, 5403-5408 (2002).
29. Gold, M. C. et al. The murine cytomegalovirus immunodomulatory gene m152 prevents recognition of infected cells by M45-specific CTL, but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo. J. Immunol. 169, 359-365 (2002).
30. Gilbert, M. J., Riddell, S. R., Plachter, B. & Greenberg, P. D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383, 720-722 (1996).
31. Reimann, J. & Schirmbeck, R. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol. Rev. 172, 131-152 (1999).
32. Orange, J. S. & Biron, C. A. Characterization of early IL-12, IFN-αβ, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J. Immunol. 156, 4746-4756 (1996).
33. Orange, J. S. & Biron, C. A. An absolute and restricted requirement for IL-12 in natural killer cell IFN-γ production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J. Immunol. 156, 1138-1142 (1996).
34. Polic, B. et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188, 1047-1054 (1998).
35. Doherty, P. C., Christensen, J. P., Belz, G. T., Stevenson, P. G. & Sangster, M. Y. Dissecting the host response to a γ-herpesvirus. Phil. Trans. R. Soc. Lond. B 356, 581-593 (2001).
36. Redpath, S., Angulo, A., Gascoigne, N. R. & Ghazal, P. Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J. Immunol. 162, 6701-6707 (1999).
37. + T cells. Nature Med. 5, 1039-1043 (1999).
38. Cebulla, C. M. et al. Human cytomegalovirus disrupts constitutive MHC class II expression. J. Immunol. 169, 167-176 (2002).
39. Liu, X., Schrager, J. A., Lange, G. D. & Marsh, J. W. HIV Nef-mediated cellular phenotypes are differentially expressed as a function of intracellular Nef concentrations. J. Biol. Chem. 276, 32763-32770 (2001).
40. Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D. & Baltimore, D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397-401 (1998).
41. Krmpotic, A. et al. The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J. Exp. Med. 190, 1285-1296 (1999).
42. Lubinski, J. M. et al. Herpes simplex virus type I glycoprotein gC mediates immune evasion in vivo. J. Virol. 72, 8257-8263 (1998).
43. Farrell, H. E. et al. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 396, 510-514 (1997).
44. + T cells and NK cells in vivo. Nature Immunol. 6, 529-535 (2002).
45. van Berkl, V. et al. Critical role for a high-affinity chemokine-binding protein in γ-herpesvirus-induced lethal meningitis. J. Clin. Invest. 109, 905-914 (2002).
46. Stevenson, P. G., Efstathiou, S., Doherty, P. C. & Lehner, P. J. Inhibition of MHC class I-restricted antigen presentation by γ 2-herpesviruses. Proc. Natl. Acad. Sci. USA 97, 8455-8460 (2000).
47. + T cells aids amplification of a latent γ-herpesvirus. Nature Immunol. 3, 733-740 (2002).
48. Munch, J., Stolte, N., Fuchs, D., Scahl-Hennig, C. & Kirchhoff, F. Efficient MHC class I major histocompatibility complex down-regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques. J. Virol. 75, 10532-10536 (2001).
49. Allen, T. M. et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407, 386-390 (2000).
50. Moore, C. et al. Evidence of HIV adaptation to HLA-restricted immune responses at a population level. Science 296, 1439-1443 (2002).
51. Goulder, P. J. et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412, 334-338 (2001).
52. Paabo, S., Bhat, B. M., Wold, W. S. M. & Peterson, P. A. A short sequence in the COCH-terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell 50, 311-317 (1987).
53. Shamu, C. E., Story, C. M., Rapoport, T. A. & Ploegh, H. L. The pathway of US11-dependent degradation of MHC class I heavy chains involves a ubiquitin-conjugated intermediate. J. Cell Biol. 147, 45-58 (1999).
54. Hewitt, E. W. et al. Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. EMBO J. 21, 2418-2429 (2002).
55. Cosman, D. et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7, 273-282 (1997).
56. Cosman, D., Fanger, N. & Borges, L. Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers. Immunol. Rev. 168, 177-185 (1999).
57. Cosman, D. et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133 (2001).
58. Arase, H., Mocarski, E. S., Campbell, A. E., Hill, A. B. & Lanier, L. L. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296, 1323-1326 (2002).
59. Smith, H. et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl. Acad. Sci. USA 19, 8826-8831 (2002).
60. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. & Masucci, M. G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen I. Proc. Natl. Acad. Sci. USA 94, 12616-12621 (1997).
61. Hill, A. et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 375, 411-415 (1995).
62. Fruh, K. et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 375, 415-418 (1995).
63. Hinkley, S., Hill, A. B. & Srikumaran, S. Bovine herpesvirus-1 infection affects the peptide transport activity in bovine cells. Virus Res. 53, 91-96 (1998).
64. Ahn, K. et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6, 613-621 (1997).
65. Bennett, E. M., Bennink, J. R., Yewdell, J. W. & Brodsky, F. M. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J. Immunol. 162, 5049-5052 (1999).
66. Gruhler, A., Peterson, P.A. & Fruh, K. Human cytomegalovirus immediate early glycoprotein US3 retains MHC class I molecules by transient association. Traffic 1, 318-325 (2000).
67. Jones, T. R. et al. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. USA 93, 11327-11333 (1996).
68. Kavanagh, D. G., Koszinowski, U. H. & Hill, A. B. The murine cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pregolgi compartment. J. Immunol. 167, 3894-3902 (2001).
69. Wiertz, E. J. H. et al. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84, 769-779 (1996).
70. Wiertz, E. J. H. J. et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384, 432-438 (1996).
71. Boname, J. M. & Stevenson, P. G. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 15, 627-636 (2001).
72. Kerkau, T. et al. The human immunodeficiency virus type-I (HIV-1) Vpu protein interferes with an early step in the biosynthesis of MHC class I molecules. J. Exp. Med. 185, 1295-1305 (1997).
73. Schubert, U. et al. CD4 glycoprotein degradation induced by human immunodeficiency virus type I Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 72, 2280-2288 (1998).
74. Ziegler, H. et al. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 6, 57-66 (1997).
75. Kavanagh, D. G., Gold, M. C., Wagner, M., Koszinowski, U. H. & Hill, A. B. The Multiple immune-evasion genes of murine cytomegalovirus are not redundant. M4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J. Exp. Med. 194, 967-978 (2001).
76. Ziegler, H., Muranyi, W., Burgert, H. G., Kremmer, E. & Koszinowski, U. H. The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. EMBO J. 19, 870-881 (2000).
77. Reusch, U. et al. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 18, 1081-1091 (1999).
78. Piguet, V. et al. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nature Cell Biol. 2, 163-167 (2000).
79. Ishido, S. et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 13, 365-374 (2000).
80. Kleijnen, M. F. et al. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER, which is not retained but is transported to the cell surface. EMBO J. 16, 685-694 (1997).